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Abstract
For the past 25 years, the Medical Research Council/Uganda Virus Research Institute Uganda 
Research Unit on AIDS has conducted research on HIV-1, coinfections and, more recently, on 
non-communicable diseases. Working with various partners, the research findings of the Unit have 
contributed to the understanding and control of the HIV epidemic both in Uganda and globally, 
and informed the future development of biomedical HIV interventions, health policy and practice. 
In this report, as we celebrate our silver jubilee, we describe some of these achievements and the 
Unit’s multidisciplinary approach to research. We also discuss the future direction of the Unit; an 
exemplar of a partnership that has been largely funded from the north but led in the south.
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Introduction
This year 2014, we celebrate 25 years of the Medical Research Council/Uganda Virus 
Research Institute (MRC/UVRI) Uganda Research Unit on AIDS. On 12th December 1988, 
the initial memorandum of understanding (MoU) between the Uganda and British 
governments was signed, leading to the establishment of MRC/UVRI. The MRC/UVRI 
research programme activities were initiated in 1989 in Kyamulibwa, in Masaka district 
(Figures 1 and 2). The unique feature of the programme has been its multidisciplinary nature 
encompassing epidemiology, clinical medicine, basic science and social science, with strong 
community development, statistical and laboratory support. Capacity building has also been 
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an important component of the Unit’s work. The theme of our celebrations is ‘25 Years of 
Research Excellence through Partnerships’ in recognition of the fact that the achievements 
and successes we have registered have only been possible through partnerships.
In 1986, the new Uganda Government recognised the danger of the HIV epidemic and acted 
quickly to make the problem public, including an appeal for international support to combat 
the disease. An invitation was extended to the United Kingdom MRC through the Uganda 
Ministry of Health to support the AIDS Control and Prevention Programme with both 
human and material resources. MRC sought support to fund the proposed HIV/AIDS 
research in Uganda and the Overseas Development Administration (ODA) – the predecessor 
of the UK Department for International Development (DFID) – agreed to fund the research. 
The MoU establishing the collaboration and the creation of the MRC/ODA/UVRI 
Programme on AIDS was signed, and the MRC was established at UVRI in Entebbe (Figure 
3).
At that time, knowledge of the epidemiology of HIV-1 in Africa was based largely on 
studies of patients attending urban hospitals and of selected urban populations such as 
antenatal care attendants; there were limited data on the extent of the epidemic among rural 
populations. Though it was known that HIV is heterosexually transmitted, there were no 
available data on risk factors for transmission or of rates of disease progression. It was 
therefore urgent that research be initiated in a rural setting to help fill these knowledge gaps 
and inform policies on prevention. The research area was selected because of proximity to 
Rakai district, where the first cases were reported in 1983 and from where the disease was 
presumed to have spread to neighbouring districts.
The programme grew considerably over the years. New research sites were opened in 
Masaka, then Entebbe, Kampala and Jinja. Working with various partners, the research 
findings of the Unit have contributed to the understanding and control of the HIV epidemic 
in Uganda and globally and informed the future development of biomedical HIV 
interventions and health policy and practice. We have tackled all aspects of the epidemic 
from basic science through to public health policy. The achievements have been possible 
through partnerships established with many different individuals and organisations. We 
summarise some of these achievements in three periods.
1989–1999
The original research investigated the epidemiology of HIV infection through annual 
surveys of a General Population Cohort (Nunn et al. 1994) with associated in-depth 
qualitative research on the impact of the epidemic in the rural setting (Seeley et al. 1993). 
Both a counselling and a community development section were set-up to support research 
activities and to promote the well-being of community members (Seeley et al. 1991; 
Nakibinge et al. 2009). Activities of this section included the establishment of various 
programmes such as school health education and community-based health care (Seeley et al. 
1992). The first ten years provided important data on HIV prevalence and incidence 
including age-specific population attributable risks for HIV-1 infection (Mulder et al. 1994; 
Kengeya-Kayondo et al. 1996). The role of sexual behaviour in the HIV-1 epidemic was 
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confirmed. The factor most strongly associated with increased risk of HIV infection was a 
greater number of lifetime sexual partners (Malamba et al. 1994). In addition, early studies 
showed that young women were at a higher risk of infection than men (Nunn et al. 1994). 
On the other hand, HIV infection among children aged 0–12 years was almost exclusively 
the result of mother-to-child transmission. No infections were attributed to parenteral 
exposure, non-sexual casual or household contact or insects (Mulder et al. 1996). Valuable 
information was generated on the biological and behavioural risk factors influencing 
transmission (Seeley et al. 1994) and the impact of the epidemic on children (Kamali et al. 
1996).
Studies showed that the proportions of deaths that would have been avoided in the absence 
of HIV were 44% for adult men, 50% for adult women and 89% for all adults aged 25–34 
years (Mulder et al. 1994). This work indicated the devastating effects of the epidemic on 
families and communities in rural areas, where the majority of Ugandans lived. In the 
mid-1990s, our work showed declining HIV prevalence, especially among young adults in 
the general population (Mulder et al. 1995) and later provided the first data on the declining 
HIV incidence in some age groups (Mbulaiteye et al. 2002). This may have been because of 
interventions in the population and suggested that some measures could lead to epidemic 
control.
In 1990, a clinical cohort of HIV-infected people called the ‘Natural History Cohort’ in the 
era before antiretroviral treatment (ART) became available was set-up to investigate clinical 
manifestations and progression of the disease (Morgan et al. 1997). Participants were seen 
routinely every three months for investigation and treatment if they were sick. This cohort 
provided important information including the survival times of HIV-infected individuals in 
subSaharan Africa which, unexpectedly, were not dissimilar to those described in high-
income countries.
In the late 1990s, the Unit contributed significantly to the understanding of the molecular 
epidemiology of HIV-1, showing that the prevalent HIV-1 subtypes circulating were A and 
D (Yirrell et al. 1998; Kaleebu et al. 2000). In late 1999, when MRC participated in the first 
HIV vaccine trial in Africa, there was intense debate as to whether using a subtype B-based 
vaccine in a region with diverse subtypes was ethical and scientifically justifiable (Mugerwa 
et al. 2002).
At the same time, a cohort of HIV-1-infected adults was established in Entebbe (Entebbe 
Cohort) to undertake a randomized trial of a polyvalent pneumococcal vaccine, in an effort 
to counter the impact of an important opportunistic infection (French et al. 2000). The 
cohort was to provide valuable information on the management of HIV and associated 
opportunistic infections in the pre-ART era (French et al. 2001; Watera et al. 2006). 
Investigations on tuberculosis–HIV interactions were initiated, such as a trial of 
prednisolone on HIV-associated tuberculosis, which revealed that prednisolone resulted in 
increased incidence of HIV-associated Kaposi’s sarcoma (Elliott et al. 2004).
The rise of non-communicable disease is a major challenge in subSaharan Africa. The Unit 
began collaborations with various partners in the mid-1990s. This work provided some key 
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insights into the impact of HIV and other factors on the risk of cancer in Uganda (Newton et 
al. 2001). Research in this area has been expanded and diversified over the last half decade, 
as non-communicable diseases have grown in relative importance as a cause of morbidity 
and mortality in low-income countries.
1999–2009
We continued to observe changes in reported sexual behaviour, especially among young 
people, who were adopting safer sex practices, but risky sexual behaviours increased in the 
middle-aged and older adults (Kamali et al. 2000; Biraro et al. 2009; Shafer et al. 2011).
While evidence for an association between HIV infection and the presence of other sexually 
transmitted diseases (STDs) was consistent in many studies (Darrow et al. 1987; Kreiss et 
al. 1988; Plummer et al. 1991), it was recognised that those STDs could just be a marker for 
sexual behaviour. A landmark study – the Masaka Intervention Trial – was a community 
randomized trial which aimed at determining the effectiveness of a behavioural change 
intervention through information, education and communication (IEC) alone or in 
combination with improved STD management on HIV transmission. There was no 
difference between intervention arms in the incidence of HIV (Kamali et al. 2003), but the 
experience gained from this trial was a stepping stone for future clinical and prevention 
trials.
During this period, the natural history cohort generated the first data on survival time in 
rural African populations, showing that survival with HIV in Africa was broadly similar to 
that in industrialised countries (Morgan et al. 2002). These data contributed to global 
estimates and projections of HIV infections. Natural history cohort data also showed that in 
women who became pregnant, CD4 cell count decline was significantly faster after 
pregnancy than before (Paal et al. 2007); that malaria had little detrimental effect on risk of 
death among HIV-infected people (Quigley et al. 2005); and that fertility is reduced from 
the earliest asymptomatic stage of HIV infection as a result of both a reduced incidence of 
recognised pregnancy and a increased fetal loss (Ross et al. 2004).
Results from a double-blind, randomized, placebo-controlled trial of the 23-valent 
pneumococcal vaccine in HIV-1-infected people in the Entebbe cohort showed no benefit in 
preventing pneumococcal disease in this population (French et al. 2000). In contrast, studies 
in the Entebbe cohort showed that co-trimoxazole prophylaxis reduced HIV mortality by 
23% and reduced rates of malaria by 68% (Watera et al. 2006). The Entebbe cohort 
provided opportunities to confirm the existence of cross-clade cellular immune responses 
(McAdam et al. 1998; Rutebemberwa et al. 2004). We demonstrated that cellular immune 
responses to the core parts of the virus correlated with slower disease progression (Serwanga 
et al. 2009) and that disease progression differed between HIV-1 subtypes A and D 
(Kaleebu et al. 2001, 2002). There was no evidence that helminth infection was associated 
with faster HIV progression (Brown et al. 2004), contrary to widely advocated hypothesis 
on the potential effects of helminth-induced T-helper (Th)2-induced immunological bias.
A major development during this decade was the introduction of antiretroviral drugs (ARVs) 
in Uganda in 2004, to treat people with HIV. Our focus changed to studying HIV-1-infected 
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patients on treatment and to design studies that could lead to simpler approaches to deliver 
ART. Using data from our cohorts, we provided feedback on the effectiveness of the ARV 
roll-out in Uganda. We also contributed to social and behavioural studies in the ART era, 
including adherence studies and cost effectiveness analyses of ART delivery strategies 
(Seeley et al. 2009; Russell & Seeley 2010; Lara et al. 2012; Mbonye et al. 2013).
The contribution of high-risk populations such as truck drivers, fishing communities and 
commercial sex workers to the epidemic was already recognised, especially along the trans-
African highway. The programme contributed studies on sexual networks and behaviours 
(Pickering et al. 1997a,b; Gryseels et al. 2002).
The Unit took part in other important clinical trials that included the DART (multicentre 
trial) and the Jinja trials, looking at simple ways of delivering ART; these showed that ART 
could be delivered safely using minimal laboratory monitoring and that structured treatment 
interruption regimens were not appropriate (DART Trial Team 2008). The Jinja trial showed 
that home-based ART delivery using trained lay workers was effective (Jaffar et al. 2010; 
Woodd et al. 2014). These two studies had a significant impact on the roll-out of ART in 
resource limited settings. Another was the cryptococcal disease prophylactic trial, which 
showed that systemic cryotococcal disease can be prevented reliably and cost-effectively 
through oral medication with fluconazole (Parkes-Ratanshi et al. 2011). The ARROW trial, 
completed in 2009, revealed that ART can be delivered to children with minimal laboratory 
monitoring (ARROW Trial team 2013).
The Unit was part of the UK Microbicide Development Programme that conducted a 
number of microbicide trials including the large phase III trial of PRO2000 which, however, 
did not show benefit in prevention of HIV transmission (McCormack et al. 2010). This 
decade also saw the initiation of long-term collaboration with the International AIDS 
Vaccine Initiative (IAVI). This partnership has helped build our capacity to conduct HIV 
vaccine trials including the conduct of two phase I vaccine trials in Masaka, but also to 
prepare cohorts for phase III efficacy trials (Ruzagira et al. 2011).
Our work gradually became a major source of data on ART drug resistance, including 
provision of data on HIV-transmitted drug resistance, with low to moderate resistance, as 
defined by WHO, reported in different populations (Ndembi et al. 2008, 2011). Further 
capacity was built to study drug resistance, with the basic sciences laboratories becoming 
the national and regional HIV drug resistance reference laboratories. These activities have 
allowed us to make a contribution to understanding of the development of resistance among 
those infected with HIV subtypes A and D (Lyagoba et al. 2010; Ndembi et al. 2010).
In 2001, work on the Entebbe Mother and Baby Study began. Addressing the hypothesis that 
maternal helminth infection might influence the infant response to BCG, the study was 
designed as a trial of anthelmintic treatment during pregnancy. In fact, at age one year, no 
effect of the intervention on responses to mycobacterial antigens was observed, but 
treatment of maternal hookworm resulted in reduced Th2 responses to tetanus antigens 
(Webb et al. 2011). In addition, there was striking evidence that maternal worm infections 
protect against eczema in childhood and that treatment of maternal worms results in 
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increased incidence of eczema (Elliott et al. 2005; Mpairwe et al. 2011, 2014). These results 
led to a broadening of the remit of the coinfection work, to explore the wider effects of 
chronic immunomodulating infections on human immunity and disease patterns and of 
maternal infections on infant immune responses.
2009–present
While our studies in the rural population continued to provide encouraging evidence that 
HIV incidence is in decline, particularly since early 2000, a reversal was seen in some age 
groups. The epidemic was shifting demographically to encompass married couples and older 
age groups. The infection rates in some high-risk populations, such as those living in fishing 
communities around Lake Victoria and commercial sex workers, had reached alarming 
proportions (Asiki et al. 2011; Seeley et al. 2012; Vandepitte et al. 2013). However, with 
the introduction of ART, survival of HIV-1-positive persons has also improved dramatically, 
and HIV has become a chronic condition with both individual and societal consequences. 
This has reduced mortality in our cohorts and resulted in a rising HIV prevalence as infected 
people survive longer. Hence, our focus during this period is changing the face of the 
epidemic with an emphasis on HIV prevention research, especially in key populations, and 
on managing HIV as a chronic disease. Interestingly, we showed that contrary to common 
belief and despite the fact that many people in high-risk populations are highly mobile, they 
still had high retention rates and could be suitable for intervention studies (Asiki et al. 2011; 
McArthur et al. 2013).
To understand the main sources of HIV infections, we took a multidisciplinary approach that 
involved identifying HIV transmission networks and linkages using molecular virology 
combined with epidemiology and social science. Similar approaches within the high-risk 
groups have shown transmission networks and linkages (Ssemwanga et al. 2012; Nazziwa et 
al. 2013) and observed that most of the transmissions occurring in the fishing communities 
come from individuals who have been infected for some time rather than incident cases.
We have therefore initiated studies to investigate factors limiting access to HIV prevention 
interventions and to assess the feasibility of conducting HIV combination interventions in 
fishing communities in Uganda. These pilot studies will inform the design of effectiveness 
trials of combination prevention in key populations and hard-to-reach communities.
In an effort to tackle the needs of the fishing communities, we are working regionally with 
other partners and have initiated the Lake Victoria Fishing Consortium, allowing a broader 
approach to intervention and health system research. Research in high-risk populations has 
allowed us to make contributions in other areas such as STDs, where we reported Neisseria 
gonorrhoea resistance to ciprofloxacin (Vandepitte et al. 2014); host immunological factors 
associated with resistance to HIV infection in highly exposed seronegative individuals (Pala 
et al. 2013); and rates of HIV-1 superinfection (Redd et al. 2014).
Studies of HIV across the life course are generating important data on the impact of HIV in 
people over 50 years living with HIV, who face particular challenges and face stigma 
because the infection is seen as a young persons’ disease (Kuteesa et al. 2012; Nyirenda et 
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al. 2013). Children/young people living with HIV have different problems, such as 
adherence and disclosure (Bernays et al. 2014; Kawuma et al. 2014).
In 2012, we became part of the International Partnership on Microbicides (IPM) by 
participating in a microbicide phase III programme evaluating the safety and efficacy of 
dapivirine (NNRTI) vaginal ring in preventing HIV-1 among sexually active HIV-negative 
women. We also successfully completed a phase I HIV vaccine trial in Masaka using Ad35-
GRIN and F4co adjuvanted with AS01B/AS01E.
We follow one of the longest treatment cohorts in Africa where many participants have been 
on ART for more than 10 years and were initiated on different first-line regimens. This 
provides an opportunity to describe the long-term safety and toxicity of ART and factors 
associated with the development of drug resistance. We have been part of a number of other 
multicentre clinical studies such as START (Babiker et al. 2013), SPARTAC (Fidler et al. 
2013) and SALIF; the latter is a phase 3b trial which will give data on a novel fixed dose 
(TDF/ 3TC/ Rilpivirine) combination, which could provide a much needed alternative to 
non-nucleoside reverse transcriptase inhibitors (NNRTI) based first-line regimen for Africa. 
Soon to be completed is the COSTOP, a study looking at the safety of discontinuing co-
trimoxazole prophylaxis among HIV-infected adults on ART in Uganda; the results will 
have important policy implications. Among children, continuing co-trimoxazole prophylaxis 
after 96 weeks of ART was beneficial compared to stopping prophylaxis, with fewer 
hospitalizations for both malaria and infection not related to malaria (Bwakura-
Dangarembizi et al. 2014).
The partnerships, infrastructure and multidisciplinary approach to research developed over 
the 25 years in the Unit are now being used to expand activities in order to address important 
research questions related to non-communicable diseases. These research questions include 
the epidemiology and genetics of communicable and non-communicable diseases, whose 
understanding is important to address the limited data on the burden and risk factors for non-
communicable diseases in subSaharan Africa. This work is beginning to generate important 
information (Maher et al. 2011; Asiki et al. 2013; Murphy et al. 2013a,b, 2014; Riha et al. 
2014).
A health systems research project was set-up in rural, semi-rural and urban settings in both 
Uganda and Tanzania (Peck et al. 2014) which plans to move into interventions research. 
Our research into mental health problems has expanded to include studies of psychiatric 
complications associated with HIV/AIDS where we see high rates of major depressive 
disorders (Kinyanda et al. 2011).
The results of the Entebbe Mother and Baby Study regarding helminths and allergy-related 
diseases have led directly to the development of a new intervention trial, the Lake Victoria 
Island Intervention Study on Worms and Allergy-related diseases (LaVIISWA). This is a 
cluster-randomised trial of intensive versus standard intervention against helminth infection, 
undertaken in island communities where the prevalence and intensity of schistosomiasis are 
particularly high.
Kaleebu et al. Page 7
Trop Med Int Health. Author manuscript; available in PMC 2015 August 08.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
As summarised above, MRC/UVRI has made significant contributions to HIV research over 
the 25 years. The initial years were aimed at understanding the new epidemic in a rural 
African setting and later in other high-risk groups. The later years allowed us to contribute 
knowledge to newer interventions and disease interactions. Our comparative advantage has 
been the multidisciplinary approach to our research and the longitudinal data and specimens. 
In response to the changing epidemic, we have also broadened our activities to non-
communicable diseases and other areas.
Capacity building
Capacity building – both in terms of people and infrastructure – has been an important part 
of our mission right from the start. This has helped establish us as an internationally 
recognised centre for research on HIV and other communicable diseases. The outcome of 
this process is a highly productive research Unit, influencing local and international policy 
and scientific thinking. The Unit has also played an important role in the capacity building 
for UVRI that includes training of staff, creating an academic environment including 
opportunities for short and long courses, seminars, supervision of staff and provision of 
laboratory space, among others (Figures 4 and 5). We have also supported the construction 
of a new clinic, training building, laboratories and other infrastructure. Over the years, we 
have created strong collaborations with various universities including Makerere University. 
More recently, the Makerere University UVRI (MUII) programme, of which we are a 
partner, has further strengthened our links to the University sector in Uganda. In the past 25 
years, we supported 44 PhD students and 74 MSc students. Some of these have gone on to 
become leaders in their field within the Unit and at other places in Uganda and elsewhere.
The future
HIV will remain a health challenge for some years to come; this epidemic remains our major 
focus, and we will continue with cutting edge research, taking advantage of our 
multidisciplinary approach and the exceptional international collaborations.
We are in a strong position to contribute to vaccine development and trials by virtue of our 
excellent laboratory facilities, our collaborations and our work on other factors that may 
influence and impair the immune response to vaccines in tropical or resource-poor settings.
We have ongoing non-communicable disease research including mental health, especially as 
it relates to infectious diseases, and working in partnerships, this will be an area of continued 
interest. New opportunities in genotyping and bioinformatics provide new avenues to 
understand the relationship between genetics and infections, non-communicable diseases 
and responses to vaccines. Indeed, two of our major cohorts have available data from 
genome-wide association studies (GWAS).
We have initiated health systems and implementation research and have important regional 
collaborations in this field. We consider this as a key cross-cutting area in which to build 
capacity. There are other areas the MRC may contribute, such as maternal and child health 
and neglected diseases.
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In all areas, we will make it a priority to build more human capacity to have more senior 
researchers as future leaders. To remain competitive, we will continue to value and 
strengthen partnerships and collaborations, including strengthening our links with UVRI and 
regional universities. This has, indeed, been 25 Years of Research Excellence through 
Partnerships.
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Figure 1. 
The laboratory at Kyamulibwa field station in 1990.
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Figure 2. 
Community meeting in Kyamulibwa, Masaka District, 2009.
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Figure 3. 
Uganda Virus Research Institute.
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Figure 4. 
Bioinformatics training being conducted at the main site in Entebbe, 2013.
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Figure 5. 
Immunology staff working on the BD LSR II flow cytometer.
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